Releviate Therapeutics Inks Exclusive License for Human Monoclonal Antibodies for Chronic Pain Indications
Releviate Therapeutics Inks Exclusive License for Human Monoclonal Antibodies for Chronic Pain Indications Therapies Based on Extensive Neuropathic Pain Research Conducted at UC Riverside and Duke University Target Chronic Pain at Its Source: Matrix Metalloproteinases SAN DIEGO — Oct. 28, 2020 — Releviate™ Therapeutics, a bio-pharmaceutical company addressing the needs of patients suffering